The End of Irreparable Damage? How the Heart’s Ability to Regrow Could Redefine Cardiology
For decades, the medical consensus was stark: once heart muscle cells died during a heart attack, they were gone for good. The resulting scar tissue was viewed as a permanent deficit, leaving the heart less capable of pumping blood and often leading to a slow slide toward heart failure.
However, new evidence is overturning this long-held assumption. Research led by specialists from the University of Sydney, the Baird Institute, and the Royal Prince Alfred Hospital has confirmed that human heart muscle cells can, in fact, regrow after a heart attack. Although this process—known as mitosis—had previously been observed in mice, this is the first time it has been verified in humans.
Moving from Management to Regeneration
The discovery shifts the conversation from simply managing the symptoms of heart disease to potentially reversing the damage. Until now, the focus of cardiovascular care was largely on preventing further damage or using devices to support a failing heart.
“Until now, we’ve thought that, because heart cells die after a heart attack, those areas of the heart were irreparably damaged, leaving the heart less able to pump blood to the body’s organs. Our research shows that while the heart is left scarred after a heart attack, it produces new muscle cells, which opens up new possibilities.” Dr. Robert Hume, Faculty of Medicine and Health, University of Sydney
The future trend in cardiology is now leaning toward regenerative medicine. The goal is not just to observe this natural regrowth, but to amplify it. By identifying the specific proteins that trigger cell division, scientists hope to develop therapies that supercharge the heart’s innate ability to heal itself.
Bridging the Heart Transplant Gap
The urgency of this research is underscored by a staggering gap in current treatment availability. In Australia, cardiovascular disease is the leading cause of death, accounting for 24 percent of all deaths. For those who survive a major cardiac event but develop heart failure, the only definitive cure is a transplant.
The numbers highlight a systemic crisis: approximately 144,000 people in Australia are living with heart failure, yet only about 115 heart transplants are performed annually. This disparity makes the development of cell-regrowing therapies a global health priority, as it could potentially eliminate the need for high-risk surgeries and long transplant waiting lists.
The Breakthrough in “Pre-Mortem” Sampling
This discovery wasn’t a fluke of observation; it was the result of a pioneering technical approach. Researchers utilized a technique developed by Professor Paul Bannon and Professor Sean Lal to analyze tissue collected from living patients during bypass surgery.
By obtaining these pre-mortem
samples from consenting individuals at the Royal Prince Alfred Hospital, the team could compare diseased areas of the heart with healthy ones in real-time. This has provided a laboratory model that is far more accurate than previous animal-based studies.
The Next Frontier: Protein-Based Therapies
The most exciting prospect for the near future is the translation of mouse-model successes to human patients. The Sydney-based team has already identified several proteins in human samples that are known to be involved in heart regeneration in mice.
“the goal is to use this discovery to produce new heart cells that can reverse heart failure. Using living human heart tissue models in our work means that we will have more accurate and reliable data to develop new therapies for heart disease.” Professor Sean Lal, School of Medical Sciences, University of Sydney
As we move forward, we can expect to witness a rise in clinical trials focusing on protein-delivery systems—potentially using nanoparticles or targeted injections—to stimulate cardiomyocyte mitosis in the scarred regions of the heart.
Frequently Asked Questions
Can this treatment cure heart failure today?
No. While the discovery that cells can regrow is groundbreaking, current natural regrowth is not sufficient to prevent the effects of a heart attack. The research is the first step toward developing therapies that can amplify this process.
How is this different from stem cell therapy?
While stem cell therapy involves introducing external cells to the heart, this research focuses on the heart’s intrinsic
ability to divide its own existing muscle cells (mitosis).
Why is the Australian data significant?
The gap between the 144,000 people with heart failure and the 115 annual transplants in Australia illustrates the desperate need for non-surgical regenerative alternatives.
What are your thoughts on the future of regenerative medicine? Do you consider we will see a world without heart transplant lists? Let us know in the comments below or subscribe to our newsletter for the latest breakthroughs in medical science.
